Lunaphore and Abcam Announce Agreement for Primary Antibody Validation for Use on COMET™, Combining Power of Trusted Antibody Provider With Superior Multiplex Capabilities
6.4.2023 18:04:00 EEST | Business Wire | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and abcam (NASDAQ: ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced an agreement to co-market abcam primary antibodies specifically validated for use on Lunaphore’s COMET™ platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005514/en/
The agreement will enable researchers to use abcam’s antibodies without conjugation directly on the COMET™ platform, with unparalleled scalability and reproducibility. By using validated primary antibodies together with the capabilities of COMET™, researchers can accelerate assay development processes and achieve reliable results. The partnership also aims to address the reproducibility crisis in life sciences by providing trusted tools for multiplex immunofluorescence analysis.
Lunaphore recently expanded its offerings to become the first universal, end-to-end solution for spatial biology research. Lunaphore’s COMET™ is the only high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. It has a wide range of research applications across multiple disciplines and drug development stages, provides walk-away automation, and allows for the generation of highly robust and reproducible hyperplex data with full tissue preservation that answers the growing needs of translational research.
“This collaboration underscores the importance we place on using antibodies from trusted and proven vendors like abcam. We understand how important it is to the research community to use antibodies that they already know and rely on and be able to directly transfer and use them for multiplexing,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “We are very proud to see how customers can already optimize and run new panels in days. Proposing validated abcam antibodies on COMET will help streamline and scale the researchers’ multiplexing capabilities even more.”
“We’re excited to be partnering with Lunaphore to offer the life science community a library of primary antibodies validated for use with Lunaphore’s automated platform for hyperplex immunofluorescence analysis,” said Courtney Nicholson, Vice President Business Development at abcam. “Spatial biology is truly revolutionizing our understanding of human health and disease, and we are pleased to be working together with Lunaphore to support researchers with the tools they need to further advance this promising new field.”
Lunaphore and abcam will present novel data together in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, highlighting shared research:
Automated multiplex immunofluorescence enables single cell analysis of tumor stroma
Poster #: 4616, Section 4
Date and time: April 18, 1:30 pm – 5:00 pm EST
Speaker: Dr. François Rivest, Application Development Team Leader, Lunaphore
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About abcam
At abcam, we believe that the scientific community goes further, faster, when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications.
We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.
To find out more, visit us at www.abcam.com and corporate.abcam.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005514/en/
Contact information
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Abcam Corporate Communications
Email : external.comms@abcam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gen Z Spending is Expected to Reach $12 Trillion by 2030. Here's Why That Doesn't Matter as Much as Brands Think12.8.2026 13:00:00 EEST | Press release
The biggest shift in consumer spending isn't generational—it's behavioral. New research from NielsenIQ (NYSE: NIQ) finds consumers across every age group are increasingly making the same calculation: where is a premium worth paying, and where can they save money instead? The result is a growing divide between premium and value products, while traditional middle-market offerings face mounting pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812239453/en/ Every generation is spending differently, but all are weighing value more carefully The findings come from NIQ's latest global report, A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, developed in collaboration with World Data Lab. While Gen X accounted for $15.2 trillion in spending in 2025 and Gen Z is expected to reach $12 trillion by 2030, the report finds that age alone no longer explains purchasing decisions. Consumers across ge
Kinguin Renews Ravelin Partnership After Cutting Ecommerce Fraud to “Industry-Leading Low”12.8.2026 12:04:00 EEST | Press release
Kinguin, a global digital games marketplace serving more than 20 million registered users, has renewed its partnership with AI-native fraud platform Ravelin. The agreement follows significant reductions in fraud and a shift to automated, scalable fraud detection. Since first partnering in 2018, Ravelin has helped Kinguin transform its approach to payment fraud. Kinguin has eliminated the need for real-time manual reviews, while overall fraud rates have declined by 87.5%. The renewal reflects growing confidence in AI-led fraud prevention at a time when ecommerce merchants face increasingly sophisticated attacks, particularly in the digital goods space where instant delivery also means instant results for fraudsters. Kinguin is where gaming and esports fans around the world can access their favorite games, choosing from almost 200 payment methods. This also makes it a magnet for fraudsters. Previously, Kinguin’s fraud team worked around the clock manually reviewing suspicious transaction
Delhaize BeLux Achieves Up to 90% Forecast Accuracy Using SymphonyAI's AI-Driven Replenishment Platform12.8.2026 10:05:00 EEST | Press release
When a grocery retailer operates under a pure B2B affiliate model, it cannot push excess inventory to its store partners — which means forecasting has to be right, or the distribution center absorbs the cost. SymphonyAI, a global leader in Vertical AI, today announced that Delhaize, part of the Ahold Delhaize Group, has deployed SymphonyAI's Demand Forecasting and Replenishment solutions across its 600-store affiliated network and five distribution centers in Belgium, replacing reactive, manually intensive ordering processes with an AI-driven, exception-based workflow. The Delhaize Le Lion / De Leeuw network has no less than 1113 stores in Belgium and Luxembourg. The store network consists of different formulas: Delhaize, Proxy, Shop&Go and louis delhaize. Customers can also shop online via www.delhaize.be, and either pick up their products at the collect points or have them delivered to their homes. Delhaize offers a wide range of over 20,000 quality products. SymphonyAI's Demand Fore
Align Technology Prevails in China Patent Infringement Action Against Angelalign12.8.2026 03:47:00 EEST | Press release
Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China ("Angel") (Hong Kong Stock Exchange: 6699.HK). In September 2025, Align filed a patent infringement action against Angel in the Jinan Intermediate People's Court, asserting Align’s patent related to extraction-gap-closure technology (CN113693748B). On August 10, 2026, the Jinan Intermediate People's Court issued a first-instance judgment finding that Angel's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringes Align's patent rights. The court further found that the related aligner products m
Entrepreneurs Invited to Apply for 2027 SPIE Startup Challenge11.8.2026 21:40:00 EEST | Press release
Entrepreneurs around the world are invited to apply for a chance to pitch their optics or photonics technologies or products to a panel of expert judges at the 17th annual SPIE Startup Challenge. SPIE, the international society of optics and photonics, holds the competition at Photonics West every January, with multiple teams walking away with cash prizes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811090450/en/ Coalesenz won first prize for their hand-held, point-of-care coagulation analyzer at the SPIE Startup Challenge at Photonics West in January 2026. More than a simple pitch competition, the SPIE Startup Challenge is an entry point into the community of high-tech business development of new products in healthcare and deep tech, with an audience of experienced photonics innovators and investors. Cash prizes of $10,000, $5,000, and $2,500 are provided by Startup Challenge Founding Partner Jenoptik. Also given is t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom